Clinical trials of anti-LINGO-1 drug to treat eye damage from MS appears to show mixed results
(Medical Xpress)—Biogen Idec Inc has released preliminary results of a phase II clinical trial (called RENEW) meant to test the effectiveness of using an anti-LINGO-1 drug called BIIB033, to treat eye damage that occurs ...